Waukesha, WI – October 13, 2011– GE Healthcare, a unit of General Electric Company (NYSE:GE), announced today FDA 510(k) clearance of an innovative technology to aid the physician in breast cancer diagnosis. GE estimates that by 2020, more than 1 million women worldwide will be examined using SenoBright*, and this technology can help lead to more productive diagnosis paths for nearly 250,000 women…

http://www.genewscenter.com/content/detail.aspx?ReleaseID=13317&NewsAreaID=2